Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Free Cash Flow (2024 - 2025)

Beta Bionics (BBNX) has disclosed Free Cash Flow for 2 consecutive years, with -$13.9 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 6.43% to -$13.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$56.2 million through Dec 2025, down 8.81% year-over-year, with the annual reading at -$56.2 million for FY2025, 8.81% down from the prior year.
  • Free Cash Flow hit -$13.9 million in Q4 2025 for Beta Bionics, down from -$6.7 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$6.7 million in Q3 2025 to a low of -$20.7 million in Q1 2025.